Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML)

Leukemia volume 14, pages 770–772 (2000)Cite this article

Yin et al1 described a monoclonal antibody (MAB), AC133, that is reactive with an epitope on the extracellular domain of a newly recognized five-transmembrane protein expressed on CD34+ early hematopoietic precursors. A second MAB, AC141, has become available which recognizes the same antigen as AC133 but a different epitope.2 Miraglia et al2 cloned the gene and showed that this gene product was also expressed on a subset of leukemia cells. Horn et al3 presented data on 30 patients with acute myeloid leukemia, 24 of whom expressed AC133, bright in nine and dim in 15. It was of note that dim AC133 staining was also seen on CD34− leukemia cells in five patients. We described aberrant antigen expression on blast cells in patients with AML4 and more recently in patients with myelodysplastic syndrome (MDS).5 We speculated that dysregulation of antigen expression in those patients may affect the antigen recognized by MABs AC133, AC141, as well as CD34.

Bone marrow aspirates (n = 3) and peripheral blood stem cell samples (n = 13), including one preparation enriched for CD34+ precursors, were obtained from normal transplant donors. Peripheral blood samples and marrow aspirates were obtained from 14 patients with AML who were not in remission, and from 16 patients with MDS (refractory anemia (RA), RA with excess blasts (RAEB) or RAEB in transformation (RAEB-T)). Samples were processed and analyzed by multidimensional flow cytometry as described.4 MABs used in the analysis included FITC-conjugated anti-CD34 (CD34 FITC), PerCP-conjugated anti-CD45 (CD45 PerCP) (both purchased from Becton Dickinson (San José, CA, USA), and AC133PE and AC141PE (Amcell Corporation, Sunnyvale, CA, USA). A second staining step using biotin-conjugated AC133 or AC141 (Amcell Corporation) and streptavidin APC (Pharmingen, San Diego, CA, USA) was added to allow for four-color analysis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW . AC133, a novel marker for human hematopoietic stem and progenitor cells Blood 1997 90: 5002–5012

    CAS  Google Scholar 

  2. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW . A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning Blood 1997 90: 5013–5021

    CAS  Google Scholar 

  3. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D . Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells (letter) Blood 1999 93: 1435–1437

    CAS  PubMed  Google Scholar 

  4. Sievers EL, Lange BJ, Buckley JD, Smith FO, Wells DA, Diagneault-Creech CA, Shults KE, Bernstein ID, Loken MR . Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry J Natl Cancer Inst 1996 88: 1483–1488

    Article  CAS  Google Scholar 

  5. Gersuk GM, Beckham G, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ . A role for tumor necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome Br J Haematol 1998 103: 176–188

    Article  CAS  Google Scholar 

  6. Stelzer GT, Shults KE, Loken MR . CD45 gating for routine flow cytometric analysis of human bone marrow specimens Ann NY Acad Sci 1993 677: 265–280

    Article  CAS  Google Scholar 

  7. Miyoshi E, Noda K, Ko JH, Ekuni A, Kitada T, Uozumi N, Ikeda Y, Matsuura N, Sasaki Y, Hayashi N, Hori M, Taniguchi N . Overexpression of alpha1-6 fucosyltransferase in hepatoma cells suppresses intrahepatic metastasis after splenic injection in athymic mice Cancer Res 1999 59: 2237–2243

    CAS  PubMed  Google Scholar 

  8. Mangi MH, Salisbury JR, Mufti GJ . Abnormal localization of immature precursors (ALIP) in the bone marrow of myelodysplastic syndromes: current state of knowledge and future directions (review) Leukemia Res 1991 15: 627–639

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants HL36444, CA15704 and CA18029 awarded by the National Institutes of Health, Bethesda, MD; HJD is also supported by a grant from the Gabriella Rich Foundation.

Author information

Authors and Affiliations

  1. Hematologics Inc., Seattle, WA, USA

    CL Green & M Loken

  2. Amcell Corporation, Sunnyvale, CA, USA

    D Buck

  3. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    HJ Deeg

  4. Department of Medicine, University of Washington, Seattle, WA, USA

    HJ Deeg

Authors
  1. CL Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Loken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Buck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. HJ Deeg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, C., Loken, M., Buck, D. et al. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML). Leukemia 14, 770–772 (2000). https://doi.org/10.1038/sj.leu.2401736

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401736

This article is cited by

Search

Advanced search

Quick links